Best Practices in the Treatment and Management of Ovarian Cancer: Expert Managed Care Strategies on the Evolving Role of PARP Inhibitors.
The introduction of PARP inhibitors has significantly changed the management of advanced ovarian cancer. These agents improve progression-free (PFS) survival when used as maintenance therapy after first-line platinum-based chemotherapy. The most benefit is for those who have genetic mutations that m...
| Publicado en: | Journal of Managed Care Medicine Vol. 28; no. 4; pp. 4 - 10 |
|---|---|
| Autor principal: | |
| Formato: | CEU pictorial tables/charts Journal Article |
| Publicado: |
National Association of Managed Care Physicians, Inc.
2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=192616485&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 192616485 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 10941525 9084 jtl: Journal of Managed Care Medicine issn: 10941525 maglogo: N pubinfo: dt: 2025 vid: 28 iid: 4 pid: 54351 pub: National Association of Managed Care Physicians, Inc. place: Glen Allen, Virginia artinfo: ui: 192616485 192616485 192616485 192616485 ppf: 4 ppct: 6 formats: fmt: @attributes: type: P tig: atl: Best Practices in the Treatment and Management of Ovarian Cancer: Expert Managed Care Strategies on the Evolving Role of PARP Inhibitors. aug: au: Westin, Shannon N. affil: Professor in the Department of Gynecologic Oncology and Reproductive Medicine at the University of Texas MD Anderson Cancer Center in Houston, TX sug: subj: Ovarian Neoplasms Therapy Poly(ADP-Ribose) Polymerase Inhibitors Therapeutic Use Disease Management Managed Care Programs Expert Clinicians Psychosocial Factors Counseling Education, Continuing (Credit) Neoplasm Recurrence, Local Poly(ADP-Ribose) Polymerase Inhibitors Administration and Dosage Genetic Screening Poly(ADP-Ribose) Polymerase Inhibitors Adverse Effects ab: The introduction of PARP inhibitors has significantly changed the management of advanced ovarian cancer. These agents improve progression-free (PFS) survival when used as maintenance therapy after first-line platinum-based chemotherapy. The most benefit is for those who have genetic mutations that make the tumor more susceptible to PARP inhibition. pubtype: Academic Journal doctype: CEU pictorial tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|